🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "major milestone" in the fight against superbug strains of the infection, according to scientists.

A Global Challenge

Cases of gonorrhoea are on the rise globally, with figures suggesting over 82 million new cases per year. Notably increased rates are seen in Africa and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The WHO has listed it as a "high-priority threat". Recent surveillance found that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Treatment Options Receive Clearance

One new antibiotic, also known as a brand name, was cleared by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts anticipate that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in the same week. This drug, which is additionally indicated for UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This authorization represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

According to data detailed in a prominent scientific publication, the new drug eradicated the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which combines two antibiotics. The research included hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have voiced optimism. Having a one-pill regimen of this kind is hailed as a "game-changer" for public health efforts. This is deemed vital to reduce the burden of the infection for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.